934 related articles for article (PubMed ID: 28028830)
21. Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
Nicklaus MD; Ludwig SL; Kettle JK
J Oncol Pharm Pract; 2018 Apr; 24(3):185-189. PubMed ID: 29284351
[TBL] [Abstract][Full Text] [Related]
22. Direct Oral Anticoagulants Vs. Enoxaparin for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose-Response Meta-analysis.
Boyd RA; DiCarlo L; Mandema JW
Clin Transl Sci; 2017 Jul; 10(4):260-270. PubMed ID: 28467656
[TBL] [Abstract][Full Text] [Related]
23. The Utility of Rivaroxaban as Primary Venous Thromboprophylaxis in an Adult Trauma Population.
Kingdon LK; Miller EM; Savage SA
J Surg Res; 2019 Dec; 244():509-515. PubMed ID: 31336243
[TBL] [Abstract][Full Text] [Related]
24. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T
J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753
[TBL] [Abstract][Full Text] [Related]
25. Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin.
Yoshida Rde A; Yoshida WB; Maffei FH; El Dib R; Nunes R; Rollo HA
Ann Vasc Surg; 2013 Apr; 27(3):355-69. PubMed ID: 23351997
[TBL] [Abstract][Full Text] [Related]
26. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
Weitz JI; Bauersachs R; Becker B; Berkowitz SD; Freitas MCS; Lassen MR; Metzig C; Raskob GE
JAMA; 2020 Jan; 323(2):130-139. PubMed ID: 31935028
[TBL] [Abstract][Full Text] [Related]
27. Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery.
Enyart JJ; Jones RJ
Ann Pharmacother; 2005 Jun; 39(6):1002-7. PubMed ID: 15886295
[TBL] [Abstract][Full Text] [Related]
28. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
[TBL] [Abstract][Full Text] [Related]
29. Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists.
Di Nisio M; Ageno W; Rutjes AW; Pap AF; Büller HR
Thromb Haemost; 2016 Jan; 115(2):424-32. PubMed ID: 26511068
[TBL] [Abstract][Full Text] [Related]
30. Rivaroxaban: an oral factor Xa inhibitor.
Thomas TF; Ganetsky V; Spinler SA
Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
[TBL] [Abstract][Full Text] [Related]
31. Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
Loke YK; Kwok CS
J Clin Pharm Ther; 2011 Feb; 36(1):111-24. PubMed ID: 21198726
[TBL] [Abstract][Full Text] [Related]
32. Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates.
Runner RP; Gottschalk MB; Staley CA; Pour AE; Roberson JR
J Arthroplasty; 2019 Apr; 34(4):729-734. PubMed ID: 30685257
[TBL] [Abstract][Full Text] [Related]
33. Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty.
Kim SM; Moon YW; Lim SJ; Kim DW; Park YS
Thromb Haemost; 2016 Mar; 115(3):600-7. PubMed ID: 26790579
[TBL] [Abstract][Full Text] [Related]
34. Efficacy, safety, and feasibility of Apixaban for postoperative venous thromboembolism prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center.
Knisely A; Iniesta MD; Batman S; Meyer LA; Soliman PT; Cain KE; Marten C; Chisholm G; Schmeler KM; Taylor JS; Fleming ND
Gynecol Oncol; 2024 Apr; 183():120-125. PubMed ID: 38368180
[TBL] [Abstract][Full Text] [Related]
35. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
Brekelmans MP; Scheres LJ; Bleker SM; Hutten BA; Timmermans A; Büller HR; Middeldorp S
Thromb Haemost; 2017 Apr; 117(4):809-815. PubMed ID: 28180233
[TBL] [Abstract][Full Text] [Related]
36. Management of Venous Thromboembolism in Morbid Obesity With Rivaroxaban or Warfarin.
Weaver P; Ng TH; Breeden T; Edwin SB; Haan B; ; Giuliano C
Ann Pharmacother; 2022 Dec; 56(12):1315-1324. PubMed ID: 35505606
[TBL] [Abstract][Full Text] [Related]
37. Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.
Okumura Y; Fukuda I; Nakamura M; Yamada N; Takayama M; Maeda H; Yamashita T; Ikeda T; Mo M; Yamazaki T; Hirayama A;
BMJ Open; 2018 Jun; 8(6):e020286. PubMed ID: 29934383
[TBL] [Abstract][Full Text] [Related]
38. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge.
Colwell CW; Collis DK; Paulson R; McCutchen JW; Bigler GT; Lutz S; Hardwick ME
J Bone Joint Surg Am; 1999 Jul; 81(7):932-40. PubMed ID: 10428124
[TBL] [Abstract][Full Text] [Related]
39. Impact of oral anticoagulation choice on healthcare utilization for the primary treatment of venous thromboembolism.
Lutsey PL; MacLehose RF; Claxton JS; Walker RF; Adam TJ; Alonso A; Zakai NA
Vasc Med; 2020 Dec; 25(6):549-556. PubMed ID: 32716254
[TBL] [Abstract][Full Text] [Related]
40. Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients.
Fung KP; Chan KH; Ng V; Tsui PT; You JHS
Cardiovasc Drugs Ther; 2019 Jun; 33(3):331-337. PubMed ID: 30888571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
